The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I dose escalation trial of STX-001, an LNP-encapsulated self-replicating mRNA expressing IL-12, in patients (pts) with advanced solid tumors.
 
Sarina Piha-Paul
Consulting or Advisory Role - CRC Oncology; Lilly
Research Funding - ABM (Inst); Alkermes (Inst); Aminex (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squib (Inst); Cancer Prevention Research Institute of Texas (CPRIT) (Inst); Chugai Pharma (Inst); Cullinan Oncology (Inst); Cyclacel (Inst); Daichi Sanko (Inst); ENB Therapeutics (Inst); Epigenetix (Inst); Genmab (Inst); Gilead Sciences (Inst); Immunity Bio, Inc. (Inst); Immunomedics (Inst); Incyte (Inst); Innovent Biologics (Inst); Jazz Pharmaceuticals (Inst); Johnson & Johnson/Janssen (Inst); Loxo (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); Nectin Therapeutics (Inst); NIH/NCI (Inst); NRG Oncology (Inst); Nurix (Inst); OncoNano Inc (Inst); Pfizer (Inst); Phanes Therapeutics (Inst); Pieris Pharmaceuticals (Inst); ProfoundBio (Inst); Puma Biotechnology (Inst); Purinomia (Inst); Replimune (Inst); Roche/Blueprint (Inst); Seagen (Inst); Strand Therapeutics, Inc. (Inst); Tallac Therapeutics, Inc. (Inst); Toragen Therapeutics, Inc. (Inst); TransThera Biosciences (Inst); ViroMissile, Inc. (Inst); Xencor (Inst)
 
Kamalesh Sankhala
Consulting or Advisory Role - Daiichi Sankyo; SpringWorks Therapeutics
Speakers' Bureau - AADi; SpringWorks Therapeutics
Research Funding - Running clinical trials from various sponsors (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo (Inst)
 
Alexander Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; QBiotics; Roche
 
Julian Quiñones
Employment - Strand Therapeutics
Stock and Other Ownership Interests - Strand Therapeutics
Travel, Accommodations, Expenses - Strand Therapeutics
 
Ryan Sowell
Employment - Strand Therapeutics
Stock and Other Ownership Interests - Moderna Therapeutics (I); Strand Therapeutics
 
Prashant Nambiar
Employment - Strand Therapeutics
Stock and Other Ownership Interests - Strand Therapeutics
Consulting or Advisory Role - 2seventy bio
 
Robert Shine
Employment - Apollo Therapeutics; Keros Therapeutics; Strand Therapeutics
Stock and Other Ownership Interests - Keros Therapeutics; Strand Therapeutics
 
Katherine Kacena
Consulting or Advisory Role - StrandTx
 
Shari Thomas
Employment - Strand Therapeutics
Consulting or Advisory Role - Strand Therapeutics
 
LeeAnn Ali
Employment - Strand Therapeutics
 
Neil Sankar
No Relationships to Disclose
 
Tasuku Kitada
Employment - Strand Therapeutics Inc.
Leadership - Strand Therapeutics Inc.
Stock and Other Ownership Interests - Strand Therapeutics Inc.
Patents, Royalties, Other Intellectual Property - Patent applications assigned to Strand Therapeutics.
Travel, Accommodations, Expenses - Strand Therapeutics
Other Relationship - Candriam Belgium
 
Jason Luke
Stock and Other Ownership Interests - Actym Therapeutics; Kanaph Therapeutics; NeoTX; Onc.AI; Pyxis; Tempest Therapeutics
Consulting or Advisory Role - Abbvie; Alphamab; Bayer; Bright Peak Therapeutics; Bristol-Myers Squibb; Hotspot Therapeutics; Incyte; Merck; Novartis; Onc.AI; Pfizer; Regeneron; Tempest Therapeutics; Werewolf Therapeutics; Xilio Therapeutics
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Ikena Oncology (Inst); Immatics (Inst); Macrogenics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Numab (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Merck
 
Georgina Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Evaxion Biotech; GI Innovation Inc; Hexal; Highlight Therapeutics; Immunocore Ireland Limited; Innovent Biologics; IO Biotech; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Regeneron; Scancell LImited; Skyline Diagnostics